Xultophy led to greater treatment satisfaction in people with type 2 diabetes compared to multiple daily injections, a new study reveals.
More participants on the DUAL VII trial preferred to stay on Xultophy treatment compared to therapy with bolus and basal injections, and had improvements in mental health.
Xultophy is a once-daily single combination injection of Tresiba (long-acting insulin degludec) and Victoza (liraglutide), a GLP-1 agonist. The drug, developed by Novo Nordisk, is designed to treat people with type 2 diabetes who’ve been unable to control blood sugar levels on other treatments.
Researchers monitored 506 adults with type 2 diabetes from 12 countries, who were either assigned Xultophy or basal-bolus treatment for 26 weeks. Prior to the study all participants had poorly controlled blood sugar levels on Lantus (insulin glargine) and metformin.
The participants were asked to complete a questionnaire after the trial to assess patient-related outcomes (PROs). Xultophy was significantly associated with better experiences for mental health, while other improvements included treatment burden and compliance.
Xultophy led to equal reductions in HbA1c, lower rates of hypoglycemia, fewer injections per day and greater weight loss, compared to those on multiple daily injections.
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said:
“Living with diabetes is a complex situation in itself, and the treatment should not add to this. We are very pleased to see that Xultophy not only helps people with type 2 diabetes reach their blood glucose targets while reducing the risk of hypoglycemia and helping them to lose weight, but does this in a simple way.”
The findings have been presented at the 2017 International Diabetes Federation Congress in Abu Dhabi, UAE.
Originally published by Jack Woodfield at Diabetes.co.uk
This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Diabetes-Cure.me and the submitting author have used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. Please read our full Disclaimer.
Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for “FAIR USE” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favour of fair use. Please read our full Disclaimer.